Dana‑Farber/Harvard Cancer Consortium cancer clinical trials site
NCTN Lead Academic Participating Site at Dana-Farber/Harvard Cancer Consortium
['FUNDING_OTHER'] · DANA-FARBER CANCER INST · NIH-11291160
This program helps Dana‑Farber/Harvard join national cancer clinical trials so adults with breast and other cancers can access new treatments.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11291160 on ClinicalTrials.gov |
What this research studies
As a patient, this program means the Dana‑Farber/Harvard Cancer Consortium acts as a lead site that opens and runs national National Cancer Institute clinical trials. It brings together Dana‑Farber, Brigham & Women's, and Massachusetts General Hospital teams to enroll patients, support investigators, and help design and manage trials. The site provides biostatistics, translational science, and multi‑modality treatment expertise across common and rarer cancers. That support aims to speed patient access to experimental therapies and to high‑quality care within well‑organized trials.
Who could benefit from this research
Good fit: Ideal candidates are adults with breast cancer or other cancers who receive care at Dana‑Farber, Brigham & Women's, or Massachusetts General and meet the specific eligibility rules of an open NCTN trial.
Not a fit: People without cancer, those receiving care far from the Boston hospitals, or patients who do not meet individual trial eligibility requirements are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, patients could have faster access to a wider range of national clinical trials and cutting‑edge cancer treatments.
How similar studies have performed: These hospitals have a long, successful history of leading and enrolling patients in NCTN trials that have produced practice‑changing results.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BURSTEIN, HAROLD JOHN — DANA-FARBER CANCER INST
- Study coordinator: BURSTEIN, HAROLD JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancer Burden, Cancer Patient